Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANNA pharmacokinetics in HIV-infected pregnant women
2024-515487-31-00Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 7
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide, tenofovir alafenamide, emtricitabine + tenofovir disoproxil, emtricitabine + rilpivirine + tenofovir disoproxil fumarate, emtricitabine + rilpivirine + tenofovir alafenamide and 18 more in human immunodeficiency virus infection (HIV), sponsored by Radboud University Medical Center. Primary endpoints: Pharmacokinetic parameters in pregnancy vs postpartum, Ctrough target attainment in pregnancy and 3 more. Started Oct 2024; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamidetenofovir alafenamideemtricitabine + tenofovir disoproxilemtricitabine + rilpivirine + tenofovir disoproxil fumarateemtricitabine + rilpivirine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-515487-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515487-31-00.